act as homodimers that represent protease-activated ligands specific for the PDGFR␣ and PDGFR␤ homodimers, respectively (4, 5) . The PDGF receptors consist of five extracellular Ig-like domains and an intracellular tyrosine kinase domain (6) . The different receptor subtypes trigger more or less similar signaling cascades that lead mainly to proliferative signals to the cell but also mediate chemotaxis or changes in actin cytoskeleton organization (7) . Interestingly, in most cell types, the ␤-receptor subtype is constitutively expressed, whereas the expression of PDGFR␣ is tightly controlled by different mitogenic or inflammatory stimuli (8, 9) . MC constitutively secrete PDGF-A at low levels, which may serve to downregulate PDGFR␣ expression and prevent proliferative responses (10) . Unopposed proliferation of MC and extensive matrix expansion are hallmarks of different forms of glomerulonephritis and PDGF has been shown to be the main player in a complex network of growth factors and inflammatory mediators in the course of kidney diseases (3, 9, 11) .
Renal MC synthesize nitric oxide (NO) after induction of the inducible form of the NO synthase (iNOS) by cytokines (12) . In MC, high amounts of NO, which can be generated by the activity of iNOS, mediate cytotoxicity, and apoptosis (13, 14) . Moreover, NO is a potent mediator of gene expression in MC.
This regulation occurs via the activation of the guanylyl-cyclase or by NO-induced changes of the redox state of the cell (15, 16) .
Since Cattell et al. reported on the synthesis of NO in glomeruli in experimental nephrotoxic nephritis in the rat (17) , the role of NO as a modulator of inflammatory kidney diseases has been thoroughly investigated. Remarkably, in a rat model of anti-Thy-1 glomerulonephritis administration of the NOS inhibitor N G -monomethyl-l-arginine (L-NMMA) drastically reduced mesangiolysis, indicating a role for NO in mediating cell death (18) . This observation was further corroborated by results that demonstrate that selective blockage of iNOS activity by l-N 6 (1-iminoethyl)lysine(dihydrochloride) (L-NIL) drastically reduces mRNA and protein levels of the chemoattractant MIP-2, and subsequently prevents neutrophil invasion (19) . By contrast, in a chronic model of the disease, the activity of iNOS is necessary to prevent intraglomerular coagulation and fibrosis (20, 21) . In cultured MC, PDGF induces proliferation (3), whereas NO antagonizes proliferative signals in MC (22, 23) . Importantly, PDGF inhibits cytokine-induced iNOS expression in MC (24, 25) , and this may shift the balance toward a proliferative state. In addition, NO was found to inhibit the expression of SPARC (secreted protein acidic and rich in cysteine), a potent inhibitor of PDGF signaling (26, 27) , and this may further contribute to a proliferative setting in the course of inflammatory glomerular diseases. Obviously PDGF and NO act in an opposing manner, and we provide a further facet in this study by analyzing the effects of NO on the expression of the different PDGFR isoforms PDGFR␣ and PDGFR␤.
Materials and Methods

Reagents
Human recombinant IL-1␤ was obtained from Cell Concept (Umkirch, Germany). Nylon blotting membranes were purchased from NEN Life Science Products (Kö ln, Germany), Immobilon P (polyvinylidene difluoride) membranes (Millipore Eschborn, Germany), media and sera were from Life Technologies-BRL (Eggstein, Germany), and tissue culture plastic was from Falcon (Becton-Dickinson, Heidelberg, Germany).
, L-NMMA, and L-NIL were purchased from Alexis (Grü nberg, Germany); PDGF-AA was from Biomol (Hamburg, Germany). PDGF-BB and all other chemicals were purchased from Sigma (Deisenhofen, Germany). Polyclonal affinity purified antibodies against PDGFR␣, PDGFR␤ (rabbit), as well as against the phosphorylated forms of p-PDGFR␣ (Tyr 720), PDGFR␣ (Tyr 731), and PDGFR␣ (Tyr 857) (all goat), actin (goat), and a monoclonal antibody against ␤-tubulin (mouse) were from Santa Cruz Biotechnologies (Heidelberg, Germany). A sheep polyclonal antibody used for the detection of PKB/Akt was from Biomol. A rabbit polyclonal antibody against serine phosphorylated PKB/Akt (pSer-473) was purchased from New England Biolabs (Frankfurt, Germany). Secondary horseradish peroxidase conjugated antibodies for goat, mouse, rabbit, or sheep IgG were purchased from Santa Cruz Biotechnologies.
Cell Culture
Rat glomerular MC were cultivated as described previously (28) and grown in RPMI 1640 medium supplemented with 10% FCS, 2 mM glutamine, 5 ng/ml insulin, 100 U/ml penicillin, and 100 g/ml streptomycin. Quiescent cells were obtained by incubating MC for 24 h in serum-free Dulbecco's minimal essential medium supplemented with 0.1 mg/ml of essentially fatty acid-free BSA before stimulation with cytokines or NO donors. Most experiments were conducted using DETA-NO as an NO donor that slowly releases NO and decomposes after first-order kinetics. We tested this compound previously and determined a half-life of 16.5 h under comparable conditions that we used for this study (29) . This fits well to the half-life of 20 h reported in the literature (30) . To confirm our results obtained with DETA-NO, we also used spermine NONOate, which decomposes with a half-life of 39 min (31) . MC were used between passages 12 and 18.
Nitrite Determination
Determination of the stable NO oxidation product nitrite in culture supernatants was performed using the Griess method (32) .
Isolation of Total RNA, Reverse-Transcription, Semiquantitative, and Quantitative PCR Total RNA from MC was isolated as described previously (33) . For reverse-transcriptase PCR (RT-PCR), 2 g total RNA were reversedtranscribed with reverse-transcriptase (MBI-Fermentas, St. Leon-Rot, Germany). Thereafter, semiquantitative PCR was performed with 22 cycles (30 s at 94°C; 45 s at 53°C, 60 s at 72°C) using the PDGFR␣-specific primers (5Ј-ATGTTTCTAGACTCGCAGCTCA 3Ј and 5Ј-ATA-AACAAAGGCAGTGATACAG-3Ј; Invitrogen, Karlsruhe, Germany) and the PDGFR␤-specific primers (5Ј-TCCAGCTGTGCCTCAG-GCTCTG-3Ј and 5Ј-GACCAGTTCTACAATGCCATCA-3Ј) that were designed according the sequences deposited in the GENBANK library [accession number: M63837 (34) and AY090783, respectively]. To correct for unequal amounts of RNA, a further PCR reaction was performed using primers 5Ј-CCTTCATTGACCTCAACTAC-3Ј and 5Ј-GGAAGGCCATGCCAGTGAGC-3Ј specific for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA. The PCR products were run in a 1% agarose gel and analyzed using a GelDoc system (BioRad, Mü nchen, Germany).
Quantitative PCR was performed using a GeneAmp 7700 System (Applied Biosystems, Weiterstadt, Germany) according to the manufacturers instructions). The reactions were performed with 40 cycles (15 s at 95°C; 1 min at 60°C). Each sample was measured in triplicate. Quantification was performed using the ⌬⌬Ct method. The following oligonucleotides were used for real-time PCR:
Forward primer: 5Ј ATCAGGCCCACCTTTGGC 3Ј (1084-1101) Reverse primer: 5Ј GGTAGGCCTGCACCTCCAC 3Ј (1162-1144) TaqMan probe: 5Ј TGGAAACTGTGAACCTGCATCAGGTCAG 3Ј (1106-1133)
To correct for unequal amounts of RNA, mRNA levels for GAPDH were analyzed using a primer set provided by Applied Biosystems.
Western Blot Analysis
Homogenates of MC or of isolated glomeruli were boiled for 5 min in Laemmli buffer and subjected to SDS-PAGE (7.5% acrylamide gel). After transfer to a polyvinylidene difluoride membrane PDGFR␣, p-PDGFR␣, PDGFR␤, p-PDGFR␤, PKB, and p-PKB were detected by using the respective antibodies. Suitable secondary antibodies and the ECL detection system (Amersham, Braunschweig, Germany) were used to visualize protein signals. To demonstrate equal loading, blots were stripped and analyzed with a monoclonal antibody against ␣-actin or ␤-tubulin.
In Vivo Model of Anti-Thy-1 Glomerulonephritis
All animal experiments were conducted according to the German law for protection of animals. Anti-Thy-1 glomerulonephritis (anti-Thy-1-GN) was induced in adult male Wistar rats weighing 180 to 200 g (Charles-River, Sulzfeld, Germany) by a single intravenous injection of mouse anti-rat Thy-1.1 IgG, clone OX-7 (BioTrend, Cologne, Germany) at a dose of 1 mg/kg body weight. Control animals were receiving a single intravenous injection of PBS only. Previous results from our group showed expression of iNOS in isolated glomeruli from antiThy-1 nephritic rats between 1 h and 16 h after injection of the antibody (19) . To find out the maximal effect of NO on the expression of PDGFR␣, kidneys were harvested at 2, 4, 8, 16, and 24 h (data not shown) and all further experiments were performed 16 h after induction of the disease.
L-NIL, a selective inhibitor of iNOS was administered intravenously at a dose of 5mg/kg body weight to control and nephritic rats 45 min before anti-Thy 1-GN was induced. Systolic BP was monitored by tail plethysmography (35) . Animals were anesthetized with hexobarbital (150 mg/kg). Kidneys were removed and glomeruli were isolated as described by Krakower (36) by sequential sieving. Glomeruli from each kidney preparation were washed three times, examined by light microscopy (purity of isolates Ͼ95%), counted thrice in a Fuchs-Rosenthal chamber, and processed for Western blotting.
Immunohistochemistry
Kidney tissue samples were fixed in 4% formaldehyde in PBS and embedded in paraffin. Sections (4-m) were stained with periodic acid-Schiff reaction and processed for immunohistochemical studies by immunoperoxidase techniques (37) . Before incubation with the primary antibody, endogenous peroxidase was blocked with 0.2% hydrogen peroxidase in methanol and endogenous biotin was blocked using the Avidin/Biotin Blocking Kit (Vector Lab, Burlingame, CA). Primary antibodies included affinity-purified rabbit anti-human PDGFR␣, goatanti-human phospho-PDGFR␣ (Tyr720) phosphorylated at Tyr720 and rabbit-anti-human PDGFR␤, which react with the respective forms of PDGFR␣ or PDGFR␤ of rat origin (dilution 1:200, applied for 1 h at 37°C), respectively. Unspecific binding was blocked with 4% fat-free milk powder/Tris-buffered saline/0.1% Triton X-100 followed by incubation for 1 h at 37°C with an affinity-purified biotinylated goat anti-rabbit IgG (Vector Lab; dilution 1:200) or biotinylated rabbit-antigoat IgG (Dianova, Hamburg, Germany; dilution 1:200), respectively. To complete the sandwich technique the conjugate of extravidin-peroxidase (Sigma, Munich, Germany; dilution 1:500) was applied for 1 h at 37°C and sections were developed with the Diaminobenzidine Substrate Kit (Vector Lab). Counterstaining was performed with methyl green. The specificity of immunostaining was tested by omitting the primary antibody and by using nonimmune serum "unspecific" IgG.
Statistical Analyses
Data are expressed as percent of controls (mean Ϯ SD). Significance was tested by Student t test or ANOVA (ANOVA) and P Ͻ 0.05 were considered to be statistically significant.
Results
Effects of DETA-NO on PDGFR␣ and PDGFR␤ mRNA Expression
To test whether PDGFR␣ and PDGFR␤ mRNA are present in MC and affected by NO, cells were stimulated for different time periods with DETA-NO (100 M) and total RNA from DETA-NO treated and untreated MC was subjected initially to semiquantitative RT-PCR. A significant increase of PDGFR␣ mRNA levels was observed between 2 h and 12 h of DETA-NO treatment and PDGFR␣ expression declined to basal levels after 24 h (Figure 1 ). By contrast, administration of DETA-NO exerted no significant changes in PDGFR␤ mRNA steady-state levels ( Figure 1) . The time-and concentration-dependency of the effects of NO on PDGFR␣ mRNA expression were further analyzed by quantitative RT-PCR. To this end, rat MC were treated for 2, 8, 12, 24, and 32 h with DETA-NO and total mRNA was subjected to real-time PCR. Similarly to the results obtained by semiquantitative RT-PCR, a marked increase of PDGFR␣ mRNA steady-state levels was observed after 2 h that returned nearly to basal levels after 24 h (Figure 2a) . In a next step, we determined the concentration of DETA-NO sufficient to induce PDGFR␣ expression. MC were treated for 8 h with different concentrations of DETA-NO. As shown in Figure 2b , 25 M DETA-NO were sufficient to significantly increase PDGFR␣ mRNA steady-state levels. Maximal induction was reached at 50 M DETA-NO and higher doses of DETA-NO were not able to further enhance PDGFR␣ mRNA expression. To exclude NO-independent effects of DETA-NO, MC were treated with spermine NONOate, a second NO donor. Comparable to the dose response data obtained by treatment with DETA-NO, a concentration of 25 M was sufficient to markedly increase PDGFR␣ mRNA steady-state levels (Figure 2c) .
Effects of DETA-NO on PDGFR␣ Protein Expression and PDGFR␣ Autophosphorylation
To confirm that changes in the mRNA steady-state levels are followed by an increase of PDGFR␣ protein, quiescent MC were stimulated for different time periods with DETA-NO (100 M) and total protein extracts were subjected to Western blotting. PDGFR␣ protein levels were markedly increased after 5 h and declined nearly to control levels after 48 h of DETA-NO treatment (Figure 3a) . Different concentrations of DETA-NO enhanced PDGFR␣ protein levels approximately two-fold, as shown in Figure 3b ; 5 M DETA-NO was sufficient to significantly increase PDGFR␣ protein levels (Figure 3b) . The PDGF receptor tyrosine kinase becomes activated by autophosphorylation of tyrosine residues, which leads to the activation of downstream signaling cascades like the PI3 kinase pathway (38) . To test whether the effect of NO on PDGFR␣ expression is functionally relevant and results in an enhanced phosphorylation of the receptor, MC were treated for 15 h with different concentrations of DETA-NO and, to induce receptor phosphorylation, additionally with PDGF-BB (20 ng/ml) 15 min before preparation of cellular extracts for Western blotting. As displayed in Figure 4a , the phosphorylation of PDGFR␣ on Tyr 720 in DETA-NO-treated samples was comparable to the NOmediated changes in PDGFR␣ protein expression, at least at . Thereafter, total protein was subjected to Western blotting and PDGFR␣ expression was analyzed using a PDGFR␣ specific antibody. Blots were reprobed using an antibody specific for ␣-actin. Bands for PDGFR␣ and ␣-actin were visualized using the ECL system and analyzed by densitometry. Values for PDGFR␣ were corrected for ␣-actin. Data shown in the upper panels are means Ϯ SD. *P Ͻ 0.05 versus unstimulated controls (c).
lower concentrations of DETA-NO (Figure 3b ). This indicates that the enhanced phosphorylation at Tyr720 is a result of enhanced PDGFR␣ expression rather than a result of NOmediated changes in the tyrosine kinase/tyrosine phosphatase equilibrium. Analysis of the same samples with a PDGFR␣ phospho-Tyr731 antibody resulted in a comparable staining as for Tyr 720 (data not shown), indicating that NO and PDGF-BB treatment similarly affects phosphorylation sites of the receptor. Similar experiments were performed using an antibody that recognizes the phosphorylated form of PDGFR␤. No differences in PDGFR␤ phosphorylation could be detected (Figure 4b ).
Effect of NO on PDGFR␣ Expression Is Mediated by Cyclic GMP
A significant effect of low amounts of NO suggests a cyclic GMP (cGMP)-directed mechanism rather than a direct effect of NO on PDGFR␣ expression (15,39,40 ). Therefore, we tested the effects of ODQ, an inhibitor of the soluble guanylyl cyclase (sGC), as well as the synthetic activator of sGC YC-1 on PDGFR␣ expression. ODQ (200 M) completely blocked the effect of DETA-NO (100 M and 200 M) on PDGFR␣ expression ( Figure 5) . A comparable inhibition was seen with NS-2028, a second sGC inhibitor (data not shown). Furthermore, YC-1 (10 M and 30 M) mimicked the DETA-NO effects and markedly upregulated PDGFR␣ protein levels (Figure 5a ). In addition, the membrane soluble cGMP analog 8-Br-PET-cGMP concentration-dependently upregulated PDGFR␣ protein levels (Figure 5b ). These data clearly indicate a cGMP-dependent action of NO on PDGFR␣ expression.
Effects of Endogenously Produced NO on PDGFR␣ Expression
Recently, Fukuoka et al. (41) reported that IL-1␤ induces PDGFR␣ expression at the transcriptional level via the transcription factors CCAAT/enhancer-binding protein ␤ and ␦ in vascular smooth muscle cells. To elucidate whether IL-1␤ triggers PDGFR␣ expression also in MC and to test whether endo- genously produced NO takes part in IL-1␤-induced PDGFR␣ expression, MC were stimulated with IL-1␤ (0.3 nM) and, to block endogenous NO formation, additionally with different concentrations of the NOS inhibitor L-NMMA for 24 h. In IL-1␤-treated MC, PDGFR␣ expression and NO formation (measured as nitrite, data not shown) was drastically increased (Figure 6 ). Co-administration of L-NMMA reduced IL-1␤-evoked PDGFR␣ expression in part ( Figure 6 ) and blunted IL-1␤-induced NO formation (data not shown). We conclude from these data that endogenously produced NO at least partially triggers IL-1␤-driven PDGFR␣ expression.
NO-Directed PDGFR␣ Expression Mediates Enhanced Susceptibility for PDGF-AA-Induced PKB/Akt Phosphorylation
PDGF signaling results in an activation of the PI3 kinase, followed by phosphorylation of PKB/Akt. To analyze further downstream signaling events triggered by NO-induced PDGFR␣ expression, MC were forced to increase PDGFR␣ expression by prestimulation with DETA-NO for 15 h. Thereafter, the cells were treated with PDGF-AA (20 ng/ml) for 15 min and subsequently extracts were analyzed for phosphorylated PDGFR␣ (pTyr720), phosphorylated PKB/Akt (pSer 473), and total PKB/Akt. As displayed in Figure 7 , prestimulation of MC with NO results in an enhanced phosphorylation of the PDGFR␣ as well as PKB on PDGF-AA exposure, thus demonstrating the functional relevance of NO-induced upregulation of PDGFR␣ expression.
NO-Dependent Regulation or PDGFR␣ in Anti-Thy-1 Glomerulonephritis
To test whether the NO-mediated upregulation of PDGFR␣ observed in cultured MC occurs also in vivo, we analyzed PDGFR␣ expression in a rat model of anti-Thy-1 glomerulonephritis. This model of mesangioproliferative nephritis shows a potent induction of the inducible NOS in the glomerulus and is therefore well suited to analyze NO-driven gene expression in vivo (19, 42, 43) . Western blot experiments using glomerular protein extracts revealed a marked upregulation of PDGFR␣ expression in rat glomeruli 16 h after injection of the anti-Thy1.1 antibody (Figure 8 ). This effect was markedly reduced in rats that were additionally treated with the iNOS-specific inhibitor L-NIL, indicating a role for NO in PDGFR␣ expression in vivo (Figure 8 ). To further evaluate whether the enhanced expression of PDGFR␣ observed in whole glomeruli is mediated by MC, immunohistochemistry was performed and PDGFR␣ expression was studied using antibodies specific for unphosphor- (Figure 9b ) was reduced in MC of nephritic rats that received L-NIL to block iNOS-driven NO formation when compared with vehicle-treated nephritic rats ( Figure 9 ). Furthermore, these effects were specific for PDGFR␣, because the immunostaining pattern and intensity of PDGFR␤ remained either unchanged or was slightly decreased in some glomeruli from nephritic rats and no differences were seen between nephritic rats which received L-NIL or vehicle (Figure 9c ).
Discussion
Both PDGF and NO have an important impact on the development and the course of several forms of inflammatory kidney diseases. At least in part, PDGF and NO act in an opposing manner. PDGF has been characterized as the main mediator of mesangial cell proliferation that may be followed by matrix deposition and eventually by sclerosis and scarring (9, 11, 44) . Large amounts of NO that are produced by iNOS after exposure of MC or invading monocytes to inflammatory cytokines exert toxic, pro-apoptotic, and anti-proliferative effects on MC in the inflamed glomerulus. Furthermore, NO potently triggers gene expression in MC and a series of genes was found to be under the expressional control by NO (15, 45) . NO exerts its effects by cGMP-dependent and cGMP-independent pathways (15,37,45). Moreover, NO-driven regulation of gene expression may occur at the transcriptional, post-transcriptional, or posttranslational level (19, 46, 47) , thereby inducing the expression of both protective and harmful gene products.
An inhibition of cytokine-induced iNOS expression by PDGF has been shown earlier in rat MC (24, 25) . Therefore, PDGF may be ideally suited to limit an extensive and deleterious NO formation observed in the early phases of glomerulonephritis (19, 48) . Because PDGF affects NO formation, it is tempting to speculate that NO in turn may also regulate the PDGF systems to maintain a homeostasis of both factors in a given setting. In line with these considerations, Callsen et al. (49) demonstrated an enhanced phosphorylation of PDGFR␤ induced by the N⌷ donor S-nitrosoglutathione, which results from an inhibition of a phosphotyrosine phosphatase activity that targets the PDGFR in rat MC. NO-mediated phosphorylation of PDGFR␤ may force cell proliferation and may therefore antagonize the antiproliferative effect of NO. We analyzed the effects of NO on PDGF receptor expression and phosphorylation and observed that NO selectively induces PDGFR␣ but not PDGFR␤ expression. Moreover, prestimulation of MC with the NO donor DETA-NO led to an enhanced PDGF-mediated downstream signaling as documented by the phosphorylation of protein kinase PKB/Akt. Therefore, NO obviously modulates PDGF signaling of both receptor subtypes by different mechanisms: the activity of PDGFR␤ is modulated by high amounts of NO in a redox-dependent manner involving the inhibition of a protein phosphatase activity (49) . By contrast, PDGFR␣ activity is enhanced by an increased receptor expression induced by low amounts of NO via an activation of the sGC/cGMP signaling pathway. This may provide an elegant mode of action by which MC are able to react to a range of concentrations of NO serving to fine-tuning PDGF-triggered signaling cascades. In this context, it is worth mentioning that MC constitutively secrete PDGF-AA that serves to downregulate PDGFR␣ surface expression. NO may overcome this physiologic feedback mechanism and reconstitute PDGFR␣ signaling. However, the detailed mechanisms that lead to the observed NO/cGMP-driven changes in PDGFR␣ expression have to be elucidated in further experiments.
Importantly, this NO-mediated changes in PDGFR␣ expression observed in cultured MC correlate well with data obtained in the rat model of anti-Thy-1 glomerulonephritis, suggesting that NO also impacts on PDGF signaling in vivo. In agreement with previous studies, the expression of PDGFR␤ remained unchanged or was even slightly reduced in some glomeruli at early stages of anti-Thy-1 glomerulonephritis (50) and appeared to be not influenced by NO. The detailed knowledge of the crosstalk between NO and PDGF signaling may help to improve strategies for the treatment of mesangioproliferative glomerular diseases, in particular when blockage of NO formation or antagonization of growth factor signaling are considered. Immunostaining for PDGFR␣ (A), p-PDGFR␣ (Tyr720) (B), and PDGFR␤ (C) in glomeruli from control and THY-1-GN kidneys. In Thy 1 nephritis, there was increased mesangial staining for PDGFR␣ (A) (brown color) and its phosphorylated form (B) (brown color) 16 h after induction of disease. Pretreatment with L-NIL reduced the intensity of staining for the phosphorylated and unphosphorylated PDGFR␣. In contrast, the immunostaining pattern and intensity of PDGFR␤ remained either unchanged or slightly decreased in some glomeruli from nephritic rats without differences between nephritic rats that received L-NIL or vehicle (C) (brown color). There was no difference in controls receiving L-NIL or vehicle. Negative controls, shown here in a tissue section from a Thy-1-nephritic kidney as an example, were performed by omitting the primary antibodies. The bar indicates magnification.
